Soluble Expression, Protein Purification and Quality Control of Recombinant Porcine Interferon-α

Jun ZHAO 1,2,3† Hai-yang YU 2† Lin GAN 2,3 Yu ZHAO 1,3

Shu-qi LI 1.3 Xiu-le FU 1.3 Ming-li WANG 1.2.3* Jason CHEN 2.4 Jacob

⁺ Jun Zhao and Hai-yang Yu contributed equally to this study and should be considered as co-first authors

¹ Wuhu Overseas Students Pioneer Park, Wuhu, Anhui Province, 241000, CHINA

² Department of Microbiology, Anhui Medical University, Hefei, Anhui Province, 230032, CHINA

³ Anhui JiuChuan Biotech Co., Ltd, Wuhu, Anhui Province, 241007, CHINA

⁴ Department of Pathology & Cell Biology, Columbia University, New York, 10032, USA

Article Code: KVFD-2017-17372 Received: 04.02.2017 Accepted: 29.05.2017 Published Online: 30.05.2017

Citation of This Article

Zhao J, Yu HY, Gan L, Zhao Y, Li SQ, Fu XL, Wang ML, Chen J: Soluble expression, protein purification and quality control of recombinant porcine interferon-a. *Kafkas Univ Vet Fak Derg*, 23 (5): 825-829, 2017. DOI: 10.9775/kvfd.2017.17372

Abstract

Herein, we reported an *Escherichia coli*-based expression and purification method of recombinant porcine interferon alpha (rPoIFN- α). PoIFN- α coding sequence was cloned into pMD18-T vector and then subcloned into pET-32a (+) vector using standard recombinant DNA techniques and the resulting plasmid was transformed into BL21(DE3) competent cells. After induction with isopropyl- β -D-1-thiogalactopyranoside (IPTG), rPoIFN- α was purified from the supernatant of the bacteria lysate using a simple two-step chromatography process consisting of a Ni²⁺ affinity chromatography and a DEAE anion exchange chromatography. rPoIFN- α was purified to >95% homogeneity with a yield of 48 mg/L of culture. It has isoelectic point of 6.09 and bacterial endotoxin was less than 1 EU/mg. N-terminal amino acid sequence and the peptide map digested by trypsin provided additional evidence for the authenticity of rPoIFN- α . The biological activity of rPoIFN- α was 1.1×10⁶ IU/mL in HEp-2/ Vesicular Stomatitis Virus (VSV) titration system and its specific activity reached to 1.0×10⁶ IU/mg. In conclusion, we obtained high-level expression of a soluble form of bioactive rPoIFN- α by using pET-32a (+) prokaryotic expression system.

Keywords: Soluble expression, Protein purification, Quality control, Porcine interferon-a, Vesicular Stomatitis Virus (VSV)

Rekombinant Domuz İnterferon-α'nın Çözünür Ekspresyonu, Protein Saflaştırması ve Kalite Kontrolü

Özet

Bu sunuda rekombinant domuz interferon alfa (rPoIFN- α)'nın *Escherichia coli*-temelli ekspresyonu ve saflaştırma metodu rapor edilmiştir. PoIFN- α kodlayan sekansı pMD18-T vektör içine klonlandı ve sonrasında standart rekombinant DNA teknikleri kullanılarak pET-32a (+) vektör içine subklonlandı ve elde edilen plazmid BL21(DE3) kompetan hücreler içine nakledildi. İzopropil- β -D-1-tiogalaktopiyranosid (IPTG) ile uyarmanın ardından rPoIFN- α , bakteri lizatının süpernatantından basit iki basamaklı kromatografi işlemi (Ni²⁺ affinite kromatografi ve DEAE anyon değişim kromatografi) kullanılarak saflaştırıldı. rPoIFN- α 48 mg/L kültür oluşumu ve >95% homojenite ile saflaştırıldı. Ürün 6.09 izoelektrik puanına sahip olup bakteriyal endotoksin 1 EU/mg'dan daha azdý. N-ucu amino asit sekansý ve tripsin ile olupturulan peptit haritasý rPoIFN- α 'nın özgünlüğü hakkında ilave kanýt saðladý. rPoIFN- α 'nın biyolojik aktivitesi HEp-2/ Vesicular Stomatitis Virus (VSV) titrasyon sisteminde 1.1×10⁶ IU/mL olarak tespit edilirken spesifik aktivitesi 1.0×10⁶ IU/mg'a ulaştı. Sonuç olarak, pET-32a (+) prokaryotik ekspresyon sistemi kullanılarak biyoaktif rPoIFN- α 'nın çözünür formunun yüksek derecede ekspresyonu sağlandı.

Anahtar sözcükler: Çözünür ekspresyon, Protein saflaştırma, Kalite Kontrol, Domuz interferon-a, Vesicular Stomatitis Virus (VSV)

INTRODUCTION

Among type I Interferons (IFNs), IFN- α plays important roles in inhibition of viral replication ^[1]. Previously,

iletişim (Correspondence)

- recombinant IFN-α has been successfully expressed in prokaryotes, eukaryotes and baculovirus ^[2-4]. However, the function of the *E. coli* expressed products was constrained by protein misfolding ^[3]. The protein expressed in *Pichia*
- *86-551-65123422 (Wang ML), +1-212-305-3310 (Chen J) Fax: 86-551-65123422 (Wang ML), +1-212-305-1262 (Chen J)
- microbio@ahmu.edu.cn (Wang ML), jc28@cumc.columbia.edu (Chen J)

was readily degradable. The baculovirus expression system does not sustain continuous high level expression.

In the present study, we represented the expression, purification, and quality control scheme for producing bioactive rPoIFN- α in large scale. It will facilitate the biological research and clinical application of porcine IFN- α .

MATERIAL and METHODS

Bacterial Strains, Reagents and Cell Lines

Molecular biology reagents were purchased from TaKaRa Biotech (TaKaRa, Dalian, China). The Ni²⁺ His-bind resin and DEAE -Sepharose Cl 6B column were obtained from GE Healthcare (Piscataway, NJ, USA). The mouse anti-PoIFN- α monoclonal antibody was purchased from Abcam (ab11408, Abcam, Cambridge, UK). The pET-32a (+) vector, *E. coli* DH5 α , *E. coli* BL21 (DE3), and HEp-2 cell line were preserved in our laboratory.

Porcine IFN-α cDNA Cloning

Total RNA was extracted from peripheral white blood cells of a 6-month-old Bamei pig and was then reverse transcribed to cDNA. The primer sequences for RT-PCR of PoIFN- α (NCBI accessing number AY345969) were 5'-GGAATTCATGTGTGACCTGCCTCAG-3' (forward) and 5'-<u>CTCGAG</u>TCACTCCTTCTTCCTGAGT-3' (reverse) which included *EcoR*I and *Xho*I sites (underlined). The amplification length was 501 bp, and It did not include the signal peptide sequence. The RT-PCR product was cloned into pMD-18T vector and the resulted recombinant plasmid was further confirmed by PCR and DNA sequencing, The final product was named as pMD18T-PoIFN- α .

Expression Vector Construction

The inserted PoIFN- α gene in pMD18T-PoIFN- α was digested by *EcoR* I and *Xho* I, and was then ligated into the pET-32a (+) plasmid. The authenticity, orientation and reading frame of the recombinant plasmid pET-32a (+)-PoIFN- α was verified by DNA sequencing.

Expression of PoIFN-a Protein

The plasmid pET-32a (+)-PoIFN- α was transformed into competent *E. coli* BL21 (DE3). The bacteria were cultured in LB medium at 37°C to a density of OD₆₀₀=0.6. After 4 h induction by IPTG, the bacteria were collected and resuspended in lysis buffer for sonication The lysate was then centrifuged and the supernatant and pellet were collected separately ^[5].

Purification of rPoIFN-a Protein

The rPoIFN- α protein in the supernatant of cell lysate was purified with Chelating Sepharose Fast Flow Ni²⁺

chromatography (GE Healthcare, Piscataway, NJ, USA) following the protocol from the manufacturer. The chromatogram were shown in Fig. 2A and Fig. 2B.

Determination of Protein Concentration and Purity

The protein concentration was determined by the Bradford method ^[6]. Reversed-phase high-performance liquid chromatography (RP-HPLC) analysis was used to determine the purity of the purified rPoIFN- α product. The integrity and specificity of the purified proteins were demonstrated by Western blot assay.

Mass Spectrometry Analysis

The purified protein was further analyzed by matrixassisted laser desorption/ionization time-of-flight mass spectrometer (MALDI-TOF MS). Mass analysis was performed using a Voyager DE-STR Biospectrometry[™] Workstation (Applied Biosystems, Foster City, CA, USA).

Determination of rPoIFN-α Biological Activity

A cytopathic effect inhibition based IFN- α bioassay ^[7] was used to evaluate the ability of the recombinant protein to protect HEp-2 cells from *VSV* infection. Data were expressed as mean unit (U)/mL, where 1 unit of IFN- α activity was defined as the reciprocal of the dilution producing 50% inhibition of CPE. The titer of sample IFN, was determined by the Reed-Muench method as previously described ^[8].

Other Quality Control Measurement of rPoIFN-a

The peptide map, isoelectric point, endotoxin, ultraviolet spectroscopy, and N-terminal amino acid sequencing of rPoIFN- α were all determined according to the guidelines in Veterinary Pharmacopoeia of People's Republic of China (2010 edition)^[9].

RESULTS


Soluble Expression of Recombinant Protein pET-32a (+)-PoIFN-a

The rPoIFN- α protein was over expressed as shown by a dominant band of 35.0 kDa in Coomassie blue stained PAGE gel (*Fig.1A*). Besides, the over-expressed protein in the *E. coli* culture was found majorly in the supernatant, not in the pellet (*Fig.1B*). By SDS-PAGE analysis, the expressed recombinant protein contituted to 32% of the total cellular protein, or 48 mg/L in *E. coli* culture.

Purification of pET-32a (+)-PolFN-α Protein

In the supernatant of cell lysate, it was shown a single protein peak by Ni²⁺ affinity chromatography (*Fig. 2A*) and by DEAE anion exchange chromatography (*Fig. 2B*). The result of purification by HPLC showed that there was a dominant protein peak with purity of 95.5% (*Fig.*

ZHAO, YU, GAN, ZHAO LI, FU, WANG, CHEN



2C). Western blot analysis with anti-PoIFN-α monoclonal antibody showed a non-enterokinase digested protein product at 35 kDa (Fig. 2D) and a enterokinase digested PoIFN-α protein at 19.3 kDa (Fig. 2D), consistent with that in SDS-PAGE gel (Fig. 1C).

induction

0.000

0.000

0.00

4.00

6.00

min

200

The purification chart of rPoIFN-α from 300 mL of bacterial culture showed that the recombinant rPoIFN- α was purified to 4.9 fold by the two-step purification procedure and its specific activity reached to 1.0×106 IU/mg (Table 1-A).

Bioactivity of Purified rPoIFN-a

35

25 20

1200

140

100

The results showed that HEp-2 cells pretreated with 1 U of purified rPoIFN inhibited 50% of VSV infection




Fig 3. Antiviral activity of the rPoIFN- α in HEp-2/VSV titration system

A: 50% of CPE inhibition by 1 unit of rPoIFN- α and 1 unit of rHuIFN- α and the control groups for the titration of biological activity of IFN, **A:** about 50% CPE was observed in *VSV* infected cells pre-incubated with 1 unit of IFN- α , **B:** about 90% CPE was observed in *VSV* infected cells without IFN- α treatment, **C:** No CPE was observed in the cells pre-incubated with 1 unit of IFN- α without *VSV* infection, **D:** No CPE was observed in the cells which was treated with neither *VSV* infection nor IFN- α addition. **B:** The dose-response curve of interferon in HEp-2/*VSV* system. The figure shows that the titre of rHuIFN- α is slightly higher than that of rPoIFN- α in human cells

Table 1-A. Purification chart of rPoIFN-a from 300 mL of bacterial culture*					
Purification Step	Total Protein (mg)	Total Activity (IU)	Specific Activity (IU/mg)	Fold of Purification	
Before purification (Cell Lysate)	77.9	1.6×10 ⁷	2.0×10 ⁵	1.0	
After two-step purification	14.5	1.4×10 ⁷	1.0×10 ⁶	4.9	
* Results were representative of three in	dependent experiments				

Table 1-B. Quality control of the bulk of rPoIFN-a					
Category	Method	Specification	Reference		
Specific activity	HEp-2/VSV	≥1.0×10 ⁶ IU/mg			
Purity	SDS-PAGE and HPLC	≥95.0%	Ref. ^[9] , Appendix 36,41		
Bacterial endotoxin	LAL(Limulus Amebocyte Lysate)	<1 EU/mg	Ref. ^[9] , Appendix 130		
Isoelectic point	Isoelectrofocusing	6.09(within 4.5~6.5)	Ref. ^[9] , Appendix 41		
UV maximum	UV scan	(278±3) nm	Ref. ^[9] , Appendix 26		
Peptide map	Tryptic digestion	Conformed to reference	Ref. ^[9] , Appendix 107		
N-terminal amino acid sequence	Edman degradation	CDLPQTHSLAHTRAL	Ref. ^[9] , Appendix 32		

(Fig. 3A). The antiviral activity of the final rPoIFN- α protein was determined as 1.1×10^6 IU/ml by the bioactivity assay. The inhibitory activity of rPoIFN- α on VSV replication in culture was dose dependent. The doseresponse curve of interferon in HEp-2/VSV system was shown in Fig. 3B.

Study on Quality Control of rPoIFN-a

The primary structure of purified rPoIFN- α was confirmed by N-terminal sequencing and Mass Spectrometry analysis (*Table 1-B*). Also, the recombinant molecules appeared to be homogenous by reversed-phase HPLC analysis and gel filtration (*Fig. 2C*) with no signs of aggregation (data not shown). The results of rPoIFN- α analysis of quality control are summarized in *Table 1-B*.

DISCUSSION

In the production of recombinant protein in heterologous expression systems, solubility is a key issue. Soluble recombinant proteins are usually properly folded, functional and they are much easier to be purified than aggregated proteins obtained from inclusion bodies.

The pET is one of the most powerful systems yet developed for the expression of the recombinant proteins in *E. coli*. The pET32 series were fused with the 109 amino acid Trx•Tag[™] thioredoxin protein which is a solubilization tag that assists in the proper folding of the expressed peptides and keeps them from precipitating. This vector also contains cleavable His•Tag[®] and S•Tag[™] sequences for detection and purification. Through the use of combination of pET-32a (+) vector and BL21(DE3) host cell, the desired expression product can comprise more than 30% of the total cell proteins in a few hours after induction ^[5].

In summary, the present study demonstrated that a functional porcine IFN- α protein was expressed in *E. coli* in a soluble form. The recombinant protein was readily purified by a two-step chromatographic procedure. Its authenticity and bioactivity were verified by multiple tests of quality control. This protein could be further expected for mass production and clinical applications of rPoIFN- α .

ACKNOWLEDGEMENTS

The research was supported by the research programs of The National Spark Program of China, (No. 2013GA710060 and No. 2014GA710014) and the programs from the Scientific Support Project of Anhui Province Education Department (No. KJ2012ZD08, KJ2012Z162) and The Innovtion Fund Technology Based Firms in China (No. 12C26213403428)

REFERENCES

1. Taylor KE, Mossman KL: Recent advances in understanding viral

evasion of type I interferon. *Immunology*, 138, 190-197, 2013. DOI: 10.1111/imm.12038

2. Wang YB, Wang ZY, Chen HY, Cui BA, Wang YB, Zhang HY, Wang R: Secretory expression of porcine interferon-gamma in baculovirus using HBM signal peptide and its inhibition activity on the replication of porcine reproductive and respiratory syndrome virus. *Vet Immunol Immunopathol*, 132, 314-317, 2009. DOI: 10.1016/j.vetimm.2009.05.017

3. Lefèvre F, L'Haridon R, Borras-Cuesta F, La Bonnardière C: Production, purification and biological properties of an Escherichia coliderived recombinant porcine alpha interferon. *J Gen Virol*, 71, 1057-1063, 1990. DOI: 10.1099/0022-1317-71-5-1057

4. Yu R, Dong S, Zhu Y, Jin H, Gao M, Duan Z, Zheng Z, Shi Z, Li Z: Effective and stable porcine interferon-alpha production by Pichia pastoris fed-batch cultivation with multi-variables clustering and analysis. *Bioprocess Biosyst Eng*, 33, 473-483, 2010. DOI: 10.1007/s00449-009-0356-3

5. Liu ZQ, Yang PC: Construction of pET-32 α (+) Vector for Protein Expression and Purification. *N Am J Med Sci*, 4, 651-655, 2012. DOI: 10.4103/1947-2714.104318

6. Kruger NJ: The Bradford method for protein quantitation. *Methods Mol Biol*, 32, 9-15, 1994. DOI: 10.1385/0-89603-268-X:9

7. Armstrong JA: Cytopathic effect inhibition assay for interferon: Microculture plate assay. *Methods Enzymol,* 78, 381-387, 1981. DOI: 10.1016/0076-6879(81)78145-X

8. Reed LJ, Muench H: A simple method of estimating 50 percent end points. Am J Hyg, 27, 493-497, 1938. DOI: 10.1093/oxfordjournals.aje.a118408

9. Commission of Chinese Veterinary Pharmacopoeia: Veterinary Pharmacopoeia of the People's Republic of China. 2010 edn., Part I, Appendix 26-130, China Agriculture Press, Beijing, 2010.